Bronfman E.L. Rothschild L.P. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 17.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,997 shares of the medical research company’s stock after purchasing an additional 737 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Amgen were worth $861,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Financial Advisory Service Inc. grew its stake in Amgen by 0.3% during the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after acquiring an additional 5 shares in the last quarter. Capital Advisors Ltd. LLC grew its stake in Amgen by 0.6% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 7 shares in the last quarter. Ballentine Partners LLC grew its stake in Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after acquiring an additional 9 shares in the last quarter. Hudock Capital Group LLC grew its stake in Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after acquiring an additional 10 shares in the last quarter. Finally, Investment Partners Ltd. OH ADV lifted its holdings in shares of Amgen by 0.5% during the 2nd quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock valued at $377,000 after buying an additional 11 shares during the last quarter. 78.38% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ AMGN) traded up $1.49 on Monday, hitting $178.69. The stock had a trading volume of 4,417,129 shares, compared to its average volume of 3,216,864. The company has a market capitalization of $128,631.35, a PE ratio of 14.09, a PEG ratio of 2.57 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen Inc. has a 1-year low of $138.83 and a 1-year high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s quarterly revenue was down .7% on a year-over-year basis. During the same period in the previous year, the business posted $3.02 earnings per share. analysts anticipate that Amgen Inc. will post 12.66 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio is presently 41.63%.
Amgen declared that its board has approved a share repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.
Several brokerages have recently issued reports on AMGN. BidaskClub upgraded Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday. Oppenheimer reiterated a “buy” rating and set a $205.00 price target on shares of Amgen in a report on Thursday. Cann reiterated a “buy” rating and set a $205.00 price target on shares of Amgen in a report on Thursday. Argus lowered Amgen from a “buy” rating to a “hold” rating and lifted their price target for the company from $175.22 to $195.00 in a report on Wednesday, November 1st. Finally, Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $190.22.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the sale, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,050 shares of company stock worth $1,239,673. 0.19% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/bronfman-e-l-rothschild-l-p-acquires-737-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.